Cite
HARVARD Citation
Chan, A. et al. (n.d.). Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology. 17 (3), pp. 367-377. [Online].